ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development) is a clinical trial[1].
Key Facts
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development) is in the country of United States[2].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s instance of is recorded as clinical trial[3].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s start time is recorded as +2018-11-12T00:00:00Z[4].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s end time is recorded as +2020-09-30T00:00:00Z[5].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s sponsor is recorded as University of North Carolina at Chapel Hill[6].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s main subject is recorded as diabetes[7].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s main subject is recorded as overweight[8].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s number of participants is recorded as {'unit': '1', 'amount': '+84'}[9].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s title is recorded as Accelerating Solutions to Optimize Glycemic Control and Weight Management In Young Adults With Type 1 Diabetes[10].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s short name is recorded as ACT1ON DP3[11].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+19'}[12].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s ClinicalTrials.gov ID is recorded as NCT03651622[13].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+30'}[14].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s research site is recorded as Stanford University[15].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s research site is recorded as University of North Carolina at Chapel Hill[16].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s research subject recruitment status is recorded as recruiting[17].
- ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)'s study type is recorded as interventional study[18].